Transmissible Spongiform Encephalopathies: Two Models for Evaluating Effects of Cleaning and Decontamination Measures on Residual Agent Infectivity Food.

Slides:



Advertisements
Similar presentations
Validating Sterilization of Medical Devices
Advertisements

Copyright © 2006 Thomson Delmar Learning. ALL RIGHTS RESERVED. 1 PowerPoint ® Presentation for Introduction to Dental Assisting Module: Disease Prevention.
CBRF Standard Precautions Training
Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.
1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.
CDRH - CBER TSE INSTRUMENT DECONTAMINATION PROJECT Stanley Brown, Katharine Merritt, Terry Woods, Scott McNamee and Deanna Busick CDRH/ OST / DMMS & DLS.
1 Clean? Disinfect? Sterilize? What does it all mean?? DA 116 Infection Control.
TSE: Instrument Management in Surgery and Dentistry Current CDC Recommendations Lynne Sehulster, PhD, M(ASCP) Division of Healthcare Quality Promotion.
3.03 Understand support services
Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.
Bovine Spongiform Encephalopathy Luke VanNatter Carrie Pell Amy Richwine Scott Inskeep Kristina Anderson.
Sterilization 4-H Veterinary Science Extension Veterinary Medicine Texas AgriLife Extension Service College of Veterinary Medicine and Biomedical Science.
Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting Gaithersburg, MD – August 1, 2011 CJD and vCJD Donor Policies: Blood and Blood.
Canadian and U.S. BSE Risk Steven Anderson, Ph.D, MPP Office of Biostatistics & Epidemiology Center for Biologics Evaluation & Research U.S. Food & Drug.
A.Selvapandiyan LBPUA, OBRR, CBER, FDA, Bethesda, MD July Multiplex fluorescence-based PCR assay to detect pathogens in blood Multiplex fluorescence-based.
Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
Results Bacteria were detected at 10 3 cells/g in un-injected controls, but none were Salmonella sp. Salmonella recovery from injected controls exceeded.
Detergent update David Gleeson Moorepark Milk Quality Workshop 2011.
1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.
IN THE NAME OF ALLAH ALMIGHTY THE MOST COMPASSIONATE THE MERCIFUL.
Bovine-derived Products Used in the Manufacture and Formulation of Vaccines and Allergenic Products: Minimizing TSE Risks William M. Egan, Ph.D. Acting.
CBER HCT/P Contamination Prevention and Biologic Product Sterility Regulations Applicable to PBSCs Cell Therapy Liaison Meeting June 16, 2006 Ellen F.
Decontamination of Surfaces Contaminated with Prions Dr. Gerald McDonnell.
FVIII PRODUCT USAGE IN CLINICAL SETTINGS TSEAC October 31, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER, FDA.
October 31, 2005HHS/FDA/CDRH1. October 31, 2005HHS/FDA/CDRH2 Scientific Issues in Evaluating Products Intended to Decontaminate Surgical instruments Exposed.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
Transmissible Spongiform Encephalopathies: Decontamination of Agent and FDA-Regulated Products Food and Drug Administration Transmissible Spongiform Encephalopathies.
Proposed algorithm for approval of human TSE tests in Europe.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.
Robert Somerville, First slide. TSE infectivity reduction during gelatine extraction processes Ad Grobben Philip J. Steele David M. Taylor Robert A. Somerville.
Laboratory of Cellular Hematology
TSEAC Meeting July 18, 2003 Topic 4 Ruth Solomon, M.D. DHT/OCTGT Methods to decontaminate facilities and equipment used in recovery and processing of HCT/Ps.
1 Laboratory of Bacterial, Parasitic and Unconventional Agents (LBPUA) Research Programs Report to BPAC 13 July 2006 Site Visit by Ad Hoc Review Committee.
TSE Clearance Studies for pdFVIII: Study Methods and Clearance Levels TSE Advisory Committee September 18, 2006 Dorothy Scott, M.D. Office of Blood Research.
19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.
TSE Advisory Committee October 25, 2001 Center for Food Safety and Applied Nutrition Food and Drug Administration Washington, DC Topic 3.
18 th Meeting of FDA TSE Advisory Committee: 31 October 2005 Summary FDA Blood Products Advisory Committee 85 th Meeting 03 November 2005 Holiday Inn Gaithersburg.
STERLIZATION AND CROSS INFECTION CONTROL IN THE DENTAL PRACTICE: part 2 BY. DR HINA ADNAN DNT 362.
C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR.
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
Draft Risk Assessment for UK manufactured Factor XI and Potential vCJD Exposure Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center.
Hong Yang, Ph.D. Office of Biostatistics and Epidemiology FDA-Center for Biologics Evaluation & Research Transmissible Spongiform Encephalopathies Advisory.
Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.
SANITATION PART 2. TYPES OF SANITATION Cleaning – physically removing all visible signs of dirt and organic matter such as feces, blood, hair, ect. Disinfecting.
Sterilization and Disinfections. Sterilization Freeing of an environment from all living microorganisms includes bacteria and their spores, fungi, parasites.
TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.
Kuru A PRION DISEASE.
Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
IN THE NAME OF ALLAH ALMIGHTY THE MOST COMPASSIONATE THE MERCIFUL.
Infection Control and Medical Asepsis
David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.
TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
INFECTION CONTROL IN DENTAL LAB Revised by: C. Heston Created by: ANKIT PRABHAKAR GENESIS INSTITUTE OF DENTAL SCIENCES AND RESEARCH,FEROZEPUR PUNJAB.
 * Sterilization: Complete destruction of all transmission m.o (bacteria,virus) * Disinfection: remove only organisms that cause disease.
3.03 Understand support services PP2
3.03 Understand support services
Regulatory Agencies And Waste Management
Lab.2- Types of Chemical Methods Sterilization
3.03 Understand support services
3.03 Understand support services
FDA TSE Advisory Committee Meeting
3.03 Understand support services PP2
3.03 Understand support services
3.03 Understand support services
3.03 Understand support services
BIOMEDICAL WASTE MANAGEMENT Submitted To – Dept.of Biotechnology Presented By – Sonika Chouhan M.Sc. II Sem.
Presentation transcript:

Transmissible Spongiform Encephalopathies: Two Models for Evaluating Effects of Cleaning and Decontamination Measures on Residual Agent Infectivity Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee 17 July 2003 Holiday Inn Bethesda, Maryland David M. Asher, MD Laboratory of Bacterial, Parasitic and Unconventional Agents Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research and Review Center for Biologics Evaluation and Research United States Food and Drug Administration address:

Participants in CBER TSE Activities (partial list) * = Participants in Decontamination Studies OBE  Steven Anderson OBRR  Dot Scott (DH)  Jaro Vostal & al (DH)  Alan Williams (DBA)  Pat McMahon*  Olga Maximova*  Pedro Piccardo*  Kitty Pomeroy*  Rolf Taffs* OCTGT  Ruth Solomon OCBQ  Jerry Davis  Maureen Knippen OD  William Freas  Diane Maloney OVRR  Christine Anderson & al  Kostantin Chumakov & al  Alfred DelGrosso  William Egan  Theresa Finn  Paul Richman

Other Participants in FDA TSE Activities (partial list) * = Participants in Decontamination Studies CDER  Yuan-Yuan Chiu  Gerald Feldman CDRH  Stanley Brown*  Charles Durfor  Katharine Merritt*  Kiki Hellman  Martha O’Lone  Celia Witten CFSAN  Marilyn Ballmer  Robert Brackett  Karen Carson  Elisa Elliott CVM  George Graber  Dragan Momcilovic  Burt Pritchett ORA  Pete Cook  Steven Solomon

Models to Evaluate Decontamination of TSE Agents Dried onto Test Surfaces: Basic Methods Agent Strain: 263K hamster-adapted scrapie, from Kimberlin R & Walker C: Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 1977;34:295 Glass slips: Modified “glass crushing spray method” from Chen JHS. Methods of testing virucides. In: Disinfection, Sterilization and Preservation, 4 th edition, ed. Block SS. (Lea & Febiger, Malvern PA) 1991 p 1087 Steel needles: Modified from Flechsig E & al. Transmission of scrapie by steel-surface-bound prions. Mol Med 2001;7:679 and Zobeley E & al. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med 1999;5:701

Dry Scrapie Agent Survives Autoclaving (263K hamster brain dried on glass)

263K Scrapie Agent as a Suspension of Hamster Brain Diluted in Phosphate-Buffered Saline Dried on Steel Needles: Assay Results Dilution Scrapie+/ Total Average Scrapie Survival (da) Range of Scrapie Survival (da) /210396, /29797, / , / /2na /2na

Study to Evaluate WHO-Recommended TSE Decontamination Regimens 1. Decontamination and cleaning procedures Infected brain tissue dried on objects  Saline suspension on glass slides  Tissue paste on steel needles Decontamination steps  Chemical soak »1N NaOH in autoclave x 30’ »NaOCl 22 o C x 60’  Autoclave (vacuum): 121 o C x 30’ or 134 o C x 90’  (in NaOH or in dH 2 0 after NaOCl soak) Cleaning: Ultrasound, detergent pH 9.45, >60 o C, 90’ Rinse: H 2 0 Terminal sterilization: Autoclave 121 o C x 20’

Study to Evaluate WHO-Recommended TSE Decontamination Regimens 2a. Assay of Residual Scrapie Infectivity: Glass Slips Positive controls: Ten slips, each with 0.1 ml of dried-on 263K scrapie-infected 10% brain suspension, ground to powder in 1 ml PBS, glass let settle, fluids pooled, 10-fold dilutions in PBS, assayed (4 hamsters per dilution intracerebrally [ic] with 0.03 ml of each sample) Tests: Each of 10 infected slips exposed to a decontamination regimen, ground to powder in PBS, fluid assayed as for control (0.03-ml samples of each ground slip into 4 hamsters ic), i.e., approx 12% of fluid assayed using a total of 40 hamsters per test, less any incidental deaths before 45 days.

Study to Evaluate WHO-Recommended TSE Decontamination Regimens 2b. Assay of Residual Infectivity: Steel Needles Positive control: Untreated samples as 10-fold dilutions of infected hamster brain in 10% (w/w) normal calf brain paste transferred to 4 wells of 96-well plastic tray, needles charged, dried, assayed (4 hamsters inoculated ic with separate needle—rotated quarter turn each direction) Test: Each of 40 needles charged with 10% scrapie hamster brain in normal calf brain, dried, treated, then tested as for control above, i.e., a total of 40 hamsters for each test, less any incidental deaths before 45 days.

Positive-Control Titration of Scrapie 263K Agent as Hamster Brain Dried on Glass (8.5 mo interim score) DilutionScrapie +/TotalAv Survival (da)Range Survival / / / / / / / , /4> /4> /4> /4>250

Positive-Control Titration of Scrapie Agent 263K in Hamster Brain, Diluted in Normal Brain, Paste Dried on Steel Needles (8.5 mo interim score) DilutionScrapie +/TotalAv Survival (da)Range Survival Control Normal0/3> / / / / / / / ,153? /4> /4> /4>250

Conclusions Methods devised to evaluate the effects of virucides are adaptable to evaluate decontamination of TSE agents. Studies with two models both suggested that exposure of 263K scrapie agent dried on surfaces to solutions of NaOH or NaOCl with simultaneous (NaOH) or sequential (NaOCl) autoclaving and ultrasonic cleaning in hot alkaline detergent markedly reduced amounts of infectivity and the risk that objects would retain detectable amounts of agent. Other chemical treatments may also be effective. Uncertainties remain:  Reliability of the decontamination procedures  Predictive value of results from the models for healthcare and manufacturing situations